◈ PeptideAtlasCONNECTED KNOWLEDGE
THE PEPTIDE REFERENCE

Mechano growth factor

Mechano growth factor refers to an IGF-1 splice-variant concept and, in many products, a synthetic E-domain fragment. Laboratory studies of that fragment have conflicting results. Exercise-related gene expression is not evidence that injecting MGF or PEG-MGF improves human muscle repair, strength, or recovery.

Also known as MGF · MGF E-peptide · IGF-1Ec E-domain

Research / unapproved usePreclinical researchBones & muscles
AI-assisted source review · 2026-10-274 cited sources2 min read

At a glance

TerminologySplice variant, precursor, and fragment are different
Common synthetic fragment24-amino-acid E-peptide
Human biology evidenceMuscle-biopsy gene-expression studies
Intervention evidenceConflicting cell experiments
PEG-MGFSeparately modified research product

Overview

The MGF label can describe different things: an IGF-1 transcript or precursor associated with mechanical loading, a short synthetic E-domain peptide, or a chemically modified product such as PEG-MGF. These are not interchangeable. Human muscle-biopsy research found changes in IGF-1 splice-variant messenger RNA after resistance exercise, which helps describe normal biology. It did not administer an MGF product. Some cell experiments reported effects of the 24-residue E-peptide on muscle progenitors, while another research group could not reproduce key effects. No approved medicine or established human recovery indication follows from this mixed preclinical literature.

Supporting sources [1] [2] [3] [4]

How it works

Alternative splicing changes the E-domain portion of IGF-1 precursor molecules while leaving the mature IGF-1 sequence conceptually distinct. Proposed independent actions of the synthetic MGF E-peptide include altered progenitor-cell proliferation and differentiation, but these effects remain disputed. Full-length IGF precursors and mature IGF-1 can behave differently from an isolated E-domain fragment. PEGylation creates another modified intervention whose exposure and safety require separate evidence.

Supporting sources [1] [2] [3] [4]

What the human exercise study measured

A small study compared IGF-1 splice-variant messenger RNA in muscle biopsies after resistance exercise in younger and older men. It found an age-related difference in the MGF transcript response. This is observational molecular evidence after exercise, not a trial showing that externally administered MGF restores youthful muscle function.

Supporting sources [1]

Conflicting laboratory findings

One study reported increased activation and fusion-related effects in cultured human muscle progenitor cells. Another group tested MGF peptides in human and mouse myoblasts and primary stem cells and did not reproduce the claimed proliferation or differentiation effects. Both results matter; omitting the unsuccessful replication overstates confidence in the proposed mechanism.

Supporting sources [2] [3]

PEG-MGF has additional unanswered questions

FDA specifically describes a lack of human exposure data and concerns about immune reactions and peptide characterization for PEG-MGF. That modified preparation should not be treated as equivalent to endogenous IGF gene expression. The available record does not establish a safe human recovery regimen or quantify long-term metabolic and tissue-growth risks.

Supporting sources [4]

Is MGF simply another name for IGF-1?

No. Mature IGF-1, an IGF-1 precursor carrying an E-domain, the isolated MGF E-peptide, and PEG-MGF differ chemically and experimentally. An outcome from one cannot be transferred to the others without evidence. This distinction is essential when evaluating claimed studies, product labels, or proposed clinical benefits.

Supporting sources [2] [3] [4]

Reading this profile

Jurisdiction: United States: no FDA-approved MGF or PEG-MGF medicine.. Molecular class: Ambiguous IGF-1 splice-variant terminology; often a synthetic E-domain peptide.

This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.

Sources & references

Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.

  1. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. ↗
    Original research · Checked 2026-10-27
  2. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. ↗
    Original research · Checked 2026-10-27
  3. Failed replication of MGF peptide effects in muscle cells ↗
    Original research · Checked 2026-10-27
  4. FDA — bulk substances with potential significant safety risks ↗
    Regulatory source · Checked 2026-10-27
CONTINUE EXPLORING

Related profiles

Abaloparatide ↗Abaloparatide is a bone-forming prescription medicine for adults with osteoporosis at high fracture risk. It activates the parathyroid hormone type 1 receptor. Its strongest fracture-prevention evidence is in postmenopausal women; the indication in men is supported by increased bone mineral density.IGF-1 DES ↗IGF-1 DES is an experimental IGF-1 variant lacking the first three amino acids of the native hormone. It interacts less strongly with certain IGF-binding proteins, altering activity in laboratory systems. Cell and animal findings do not establish human muscle-building efficacy, a safe administration regimen, or regulatory approval.IGF-1 LR3 ↗IGF-1 LR3 is a laboratory growth-factor analog with an N-terminal extension and an arginine substitution. These modifications reduce binding to certain IGF-binding proteins and alter biological potency. Human therapeutic benefit is not established, and animal research raises concern that growth stimulation can also accelerate tumor growth.Mecasermin ↗Mecasermin is an approved IGF-1 replacement medicine for specific severe pediatric growth disorders. It is not interchangeable with growth hormone and is not an approved bodybuilding or anti-aging therapy; hypoglycemia, tissue overgrowth and malignancy-related precautions are central to its use.Somapacitan ↗Somapacitan is a long-acting growth-hormone analog used for adult GH deficiency and specified pediatric growth disorders. Current U.S. labeling extends beyond pediatric GH deficiency to selected small-for-gestational-age, Noonan syndrome and idiopathic short-stature populations from age two and a half.Somatropin (rhGH) ↗Somatropin is recombinant human growth hormone with established, product-specific indications in GH deficiency and selected growth or wasting conditions. It is not an approved general anti-aging treatment, and excess exposure can cause metabolic, fluid-retention and growth-related complications.